Загрузка...
New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response
A recent decision by the Food and Drug Administration (FDA) to declare various brands of levothyroxine bioequivalent has provoked objections from several physicians' organizations. These organization assert that the method of testing bioequivalence is flawed, and that indiscriminate switching a...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer-Verlag
2005
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2751497/ https://ncbi.nlm.nih.gov/pubmed/16146330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/aapsj070107 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|